Is specialty rare-endocrinology the next hot biotech sub-vertical — and are Neurocrine (NBIX) and Vertex (VRTX) the listed expressions?
Is specialty rare-endocrinology the next hot biotech sub-vertical — and are Neurocrine (NBIX) and Vertex (VRTX) the listed expressions?
The question
Vertex's ~$10B, ~100%-premium acquisition of Crinetics (CRNX) may have validated specialty rare-endo as the next niche to "get hot," analogous to renal 3-4 years ago. Neurocrine (NBIX) already validated the anchor CAH market with Crenessity. Is this a durable sub-vertical worth positioning in NBIX (incumbent) and VRTX (adding an endo leg to CF+renal)?
Why it matters
Diversifies the book into a biotech vertical with structurally attractive economics — "no target risk, very little competitive dynamics, large unmet need" (Schimmer). A validated, newborn-screened patient pool (CAH) de-risks the commercial ramp in a way most rare diseases don't.
What we currently believe
Early/promising. The Vertex/Crinetics deal is a real validation signal, and CAH's screening profile is a genuine commercial de-risker — but "hot sub-vertical" is a narrative call, and Vertex may have overpaid (~100% premium).
Evidence we have
- paul-matteis in 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026: "This sort of specialty, rare endo space has kind of quietly become pretty hot and it feels like it's sort of the next little niche space to get hot and become its own little sub vertical."
- josh-schimmer in 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026: "Endo is one of my favorite spaces because there's essentially no target risk, there's very little in the way of competitive dynamics, there's large unmet medical needs."
- paul-matteis in 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026: (on the anchor market) Neurocrine "validated that that is a huge market via their drug Crenessity; it's on newborn screening, so there's a lot of patients out there right away that you don't have to find."
Evidence we need
- A second validating M&A deal or a Ph3 readout in rare-endo (beyond Crinetics) confirming it's a vertical, not a one-off.
- Atumelnant (Crinetics CAH Ph3) safety — Matteis flagged "seven liver enzyme elevations, higher than I had heard before."
- A valuation pass on NBIX confirming the read-through isn't already priced.
How to resolve
Track atumelnant Ph3 data and any further rare-endo M&A; watch NBIX Crenessity uptake.